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Materials and Methods
Plant growth. Plants were grown on a soil:vermiculite:perlite (2:1:1) mixture at 20ºC under constant illumination with cool white fluorescent light, unless indicated otherwise.
Tissue collection for gene expression profiling experiments.
For all experiments, we used approximately 4 week-old 35S:AP1-GR ap1-1 cal-1 plants (S1). For each sample, inflorescence tissue from ~25 plants was collected using jeweler's forceps as previously described (S1). At least four biologically independent sets of samples were generated for each experiment. For the time-course experiments, we treated inflorescences with a solution containing 10 µM dexamethasone (Sigma-Aldrich), 0.01% (v/v) ethanol, and 0.015% (v/v) Silwett L-77 (De Sangosse), or with an identical mock solution that lacked dexamethasone.
Using plastic pipettes, the solutions were directly applied onto the inflorescences so that the cauliflower-like structures were completely drenched. We then collected inflorescence tissue after 2, 4, 8, and 12 hours, as well as from untreated plants (0 hour time point). For cycloheximide experiments, we treated inflorescences of 35S:AP1-GR ap1-1 cal-1 plants with a dexamethasone-containing or a mock solution (as described above), or with identical solutions that contained in addition 10 µM cycloheximide (Sigma-Aldrich). Tissue was collected 3 hours after the treatment. For qRT-PCR experiments, tissue was collected from untreated control plants, and from plants 12 hours after treatment with either a dexamethasone-containing or a mock solution (as described above).
RNA preparation. Total RNA was isolated from tissue samples using the Plant Total RNA kit (Sigma-Aldrich) according to the manufacturer's instructions. Quality of RNA samples was evaluated using a Bioanalyzer and a RNA Nano 6000 kit (Agilent). RNA concentrations were determined using a Nanodrop ND-1000 spectrophotometer (Thermo Fisher Scientific).
Total RNA preparations used for qRT-PCR analysis were treated with DNase I (Ambion) to reduce contaminations with genomic DNA.
Microarray setup and experiments. Two different microarray platforms were used in the study: microarrays that were based on the Arabidopsis Genome Oligo Set Version 1.0 and on the Arabidopsis Genome Oligo Set Version 1.0 Upgrade (Operon, Huntsville, AL), and hereafter referred to as "Operon microarrays"; and custom microarrays manufactured by Agilent (Agilent Technologies, Santa Clara, CA), and hereafter referred to as "Agilent microarrays". The Operon microarrays were prepared as previously described (S2), and consist of a total of 30,194 70-mer oligonucleotide probes that correspond to 26, 215 annotated genes according to The Arabidopsis Information Resource (TAIR) genome annotation version 8. Agilent microarrays (version 1) were designed using the eArray software pipeline (https://earray.chem.agilent.com/earray/) and TAIR genome annotation v7, and contain 26,566 60-mer probes corresponding to the same number of annotated genes (pseudogenes, transposons, retrotransposons, and pre-tRNAs were excluded from the design). A second-generation Arabidopsis custom eArray was designed using TAIR genome annotation v8, and contains probes corresponding to 28,327 annotated genes. The same sets of RNA samples were analyzed using both the Operon and Agilent microarrays.
Operon microarrays were used as previously described (S1), except that the Amino Allyl MessageAmpII aRNA Amplification Kit (Applied Biosystems/Ambion, Austin, TX) was used for labeling of RNA samples with Cy3 and Cy5 fluorescent dyes, following manufacturer's instructions. Microarrays were scanned with both Axon GenePix 4200A and Axon 4000B scanners, using the Gene Pix 5.0 analysis software (Molecular Devices, Sunnyvale, CA).
Agilent microarrays were used following manufacturer's instructions. RNA samples were labeled with fluorescent dyes using the Quick Amp Labeling Kit (Agilent). Microarray hybridizations (65ºC, 16h) and washes were performed with Agilent reagents and following standard protocols. Microarrays were scanned using an Agilent DNA Microarray Scanner G2565CA, and data were acquired using Agilent's Feature Extraction Software version 9.5.3.1. Agilent version 1 custom microarrays were used for the time series experiments, whereas version 2 microarrays were used for the cycloheximide experiment (see below).
Four independent sets of biological samples were used for the experiments, and sample setup and pairing for hybridizations was the same for Operon and Agilent microarrays. In each of the biological replicates of the time course experiments, all the samples derived from dexamethasone (Dex)-treated plants were labeled with one dye (i.e., Cy3), and all the samples derived from the corresponding Mock-treated plants were labeled with the alternative dye (i.e., Cy5). The dyes used for labeling RNA from a given treatment type (Dex and Mock) were switched for two of the replicate experiments, to reduce dyerelated artifacts. Dex-and Mock-derived samples for each timepoint and biological replicate were co-hybridized. This experimental setup resulted in a total of 5 hybridizations per set (0h, 2h, 4, 8h, and 12h; Dex vs. Mock at each timepoint), and two biological replicate sets labeled with each dye polarity (Mock-Cy3/Dex-Cy5, and vice versa). In the cycloheximide (Chx) experiments, samples from each biological replicate resulted in a set of four hybridization pairs: Mock vs. Dex, Mock vs. Chx, Mock vs. Dex+Chx, and Chx vs.
Dex+Chx. Dye polarities were switched between biological replicates. An additional microarray experiment, a comparison between ap1-1 mutant and wild-type inflorescences, was also carried out using Agilent version 1 microarrays. The samples used in this experiment corresponded to the inflorescence meristem and floral buds, and have been described previously (S2). Three sets of biological replicates were used, and dye polarities were switched between them.
Microarray data analysis. Raw data from the Operon microarrays, and feature extraction software pre-processed data from the Agilent Microarrays, were imported into the Resolver gene expression data analysis system version 7.1 (Rosetta Biosoftware, Seattle, WA) and processed as described (S1). Resolver uses a platform-specific error model-based approach to stabilize the variance estimation to improve the specificity and sensitivity in differential gene expression detection (S3) . The data from the four biological replicates of each condition were combined, resulting in an error-model weighted average of the four. The Pvalues for differential expression calculated by Resolver were adjusted for multi-hypothesis testing using the Benjamini & Hochberg procedure, as implemented in the Bioconductor multtest package in R (http://www.bioconductor.org/packages/bioc/stable/src/contrib/html/multtest.html). Genes for which the Benjamini & Hochberg-adjusted P-value was <0.05 in at least one of the comparisons (i.e., timepoints, for the time-course experiment) and microarray platforms used (Agilent and/or Operon) were initially considered differentially expressed in response to AP1 activation (Table S1 ). In the time course experiment, genes that were differentially expressed at timepoint 0h were excluded from the analysis. A further selection was implemented by applying an absolute fold-change (FC) cutoff of 1.8, and resulted in the identification of a total of 1,370 genes that showed robust expression changes during the time-course experiment ( Table S1 ). Genes that were detected as differentially expressed in the Agilent time-course experiment (1017 genes) were subjected to cluster analysis using the k-means algorithm implemented in Resolver ( Fig. 1B ; Table S9 ). Data from the cycloheximide experiment, in which Agilent version 2 microarrays were used, were processed in Resolver in the same manner, using a Benjamini & Hochberg-corrected P- With these datasets, genes that responded to AP1 activation in the presence of Chx (and are therefore potential direct AP1-targets), were identified using three different methods. First, genes were selected if they were detected as differentially expressed upon both the Dex and Dex+Chx treatments but not upon the Chx treatment. Second, the Ratio-Split and Re-Ratio functions of Resolver 7.1 were used to computationally generate Chx vs. Dex+Chx comparisons, from which differentially expressed genes were selected with the same cutoffs indicated above. Last, differentially expressed genes were also identified from the direct Chx vs. Dex+Chx hybridizations. Combining these three strategies, a total of 1,578 genes were identified as potential AP1 targets (Table S5) . Data from the comparison between ap1 mutant and wild-type inflorescences were also processed in Resolver.
qRT-PCR experiments. cDNA synthesis was performed using DNase I-treated total RNA preparations (see above), oligo-dT primers and the RevertAid H Minus M-MuLV reverse transcriptase (Fermentas). Relative transcript abundance of selected genes (see Table S11 for a list of genes and the primers used) was determined using the Roche LightCycler 480 system and the LC480 SYBR Green I Master kit (Roche Applied Sciences). Measurements were taken for three biologically independent sets of samples. In addition, all samples were analyzed twice. LightCycler melting curves were obtained for the reactions, revealing single peak melting curves for all amplification products. The amplification data were analyzed using the second derivative maximum method, and resulting Cp values were converted into relative expression values using the comparative Ct method (S4). Two reference genes ('REF1' and 'REF2'; see Table S11 ) (S5) were used to normalize the data. Their Cp values were averaged for each sample. consensus sequences were located in the 1,000-bp region around the maximum peak score position. The sequences of the regions were extracted from the Arabidopsis reference genome (ATH1.1con.01222004; ftp://ftp.arabidopsis.org/). In order to show the dependency of the enrichment on CArG boxes on the peak score value, only a region of 250-bp around the maximum peak score position was considered. For each score threshold considered, the proportion of significant peaks containing at least one CArG box was estimated. A controlset of sequences was obtained by randomly permuting the nucleotide positions for each original 501-bp sequence, and CArG-box motif consensus sequences were located on the permuted sequences. This procedure was repeated 100 times to obtain the mean and the standard deviation of the proportion of significant peaks containing at least one CArG-box motif when the nucleotide sequences are permuted.
Antibodies
All ChIP-Seq peaks were characterized by the relative position of the peak center (maximum score position) with respect to the 5' and 3' end of all annotated genes (as described in the TAIR8_GFF3_genes.gff file, ftp://ftp.arabidopsis.org/). Genes with at least one AP1 ChIP-Seq peak located within the region from 3 kb upstream of the 5'-end to 1kb downstream of the 3'-end of the annotated transcript were considered as putative AP1 direct target genes (a total of 2,298 genes). In the majority of cases, the 5'-end of the annotated transcript marked the transcriptional start site (TSS). Out of 28,244 genes encoded in the Arabidopsis nuclear genome (TAIR8), 18,937 (67%) were annotated with a 5' UTR, 19,893
(70%) with a 3' UTR, and 18,331 (65%) with both 5' and 3' UTRs. For the 2,298 genes identified as putative direct AP1 targets, the percentages were 79.7 % (5' UTR), 82.5 % (3' UTR), and 78.2 % (5' and 3' UTR).
In order to estimate the level of enrichment of AP1 binding events in a region close to the start of genes, the method of Storey was applied (S9). In brief, given a set of values coming from two distributions, a uniform distribution representing the background level,
and an unknown non-uniform distribution, representing the enriched positions, the proportion of values coming from each of these distribution is calculated separating the two densities.
To determine the overlap between the AP1 binding sites identified in this study and those determined for SEP3 (S8), AP1 and SEP3 sites in each common putative direct target gene were paired as follows. For each gene, the relative peak position regarding the 5' end of the gene (if the peak is upstream of the gene), the 5' end weighted by the length of the gene (if the peak is located inside the gene), or the 3' end (if the peak is downstream) was used to unequivocally associate significant (FDR<0.001) AP1 peaks with their closest significant (FDR<0.001) SEP3 peaks. When two or more AP1 peaks had the same closest SEP3 peak, the SEP3 peak was assigned to the closest AP1 peak, and the other AP1 peaks were assigned to the next closest SEP3 peak (if any). In addition, the overlap between the AP1 and SEP3 binding sites was also determined considering all possible AP1-SEP3 peak pairs per target gene, i.e., in a manner that was not peak-position directed (Fig. S10 ).
ChIP-qPCR experiments. qPCR experiments were performed on immunoprecipitated DNA that was obtained using the GR antibody (see above) and tissue collected from untreated control plants, and from plants 2 and 12 hours after treatment with a dexamethasone-containing solution (as described above). qPCR experiments were done as two or more technical replicates using a Bio-Rad MyIQ Cycler and Bio-Rad iQ SYBR Supermix. Primers used for PCR amplification were designed surrounding the position of maximum height in the corresponding peak (i.e., the peak center) identified in the ChIP-Seq experiments, using the Primer3 program (http://frodo.wi.mit.edu/primer3/) ( Table S12 ). The qPCR data were analyzed using the Biogazelle qBasePlus version 1.3 program. Two reference genes were used for normalization (see Table S12 ).
Analysis of nuclear AP1-GR accumulation.
Inflorescence tissue was collected from ap1-1 cal-1 double mutants and from 35S:AP1-GR ap1-1 cal-1 plants at different time points after treatment with a dexamethasone-containing or a mock solution (as described above). The tissue was immediately frozen in liquid nitrogen. For each sample, nuclei were extracted by grinding 500 mL tissue in liquid nitrogen, followed by addition of 250 mL M1 buffer (10 mM Na phosphate pH7.0, 100 mM NaCl, 1 M hexylene glycol (Sigma), 10 mM 2-mercaptoethanol (Sigma), 1x Complete Protease Inhibitor Cocktail (CPIC; Roche)). The tissue was then ground again on ice and 650 mL M1 buffer were added. Subsequently, the cell suspension was filtered twice through Miracloth (Calbiochem) and the extract was centrifuged at 7,600xg, 5ºC for 1 min to pellet the nuclei. The supernatant was removed and the pellet washed in 900 mL M2 buffer (10 mM Na phosphate pH7.0, 100 mM NaCl, 10 mM MgCl 2 , 0.5% (v/v) Triton X-100 (Sigma), 1 M hexylene glycol, 10 mM 2-mercaptoethanol, 1x CPIC), followed by centrifugation at 7,600xg, 5ºC for 1 min. Washes with M2 buffer were repeated twice. Subsequently, the pellet was resuspended in 900 mL M3 buffer (10 mM Na phosphate pH7.0, 100 mM NaCl, 10 mM 2-mercaptoethanol, 1x CPIC) and centrifuged at 2,000xg, 5ºC for 5 min. The pellet was then resuspended in 20 mL
ChIP dilution buffer (16.7 mM Tris-HCl pH8.1, 167 mM NaCl, 1.2 mM EDTA, 1.1% (v/v) Triton X-100, 0.01% (w/v) SDS, 1x CPIC) and sonicated at high intensity for 5 cycles of 30 sec using a Bioruptor (Diagenode). The resulting nuclear extract was centrifuged at 20,000xg, 5ºC for 10 min to pellet membranes and insoluble proteins. After centrifugation, equal amounts of protein from the supernatants of the different samples were separated on 12% SDS-PAGE gels, followed by transfer to a PVDF membrane and staining with Ponceau S. AP1-GR was detected using a polyclonal antiserum raised in rabbit against the rat glucocorticoid receptor (Affinity Bioreagents #PA1-516) at a final concentration of 2 mg/mL in PBS-T (1xPBS with 0.05% (v/v) Tween 20) supplemented with 5% (w/v) milk powder. Histone 2A/B was detected using a polyclonal antiserum raised in rabbit (a gift from Dr. Thomas Kretsch, University of Freiburg), which was diluted 10,000-fold in 5%
(w/v) milk PBS-T. The immunoblots were developed using horseradish peroxidase-coupled anti-rabbit IgG antibodies (Sigma; diluted 50,000-fold in PBS-T) and the ECL+ detection kit (GE) or the ECL kit (Pierce) for AP1-GR and histone 2A/B, respectively, according to the manufacturers' instructions. Both constructs were derived from pASM4, by replacing the 3' sequence downstream of the stop codon with shorter 3' fragments. These fragments were generated by PCR amplification and were subcloned using naturally occurring restriction sites in the TFL1 genomic sequence. Full details of the cloning strategy are available upon request (madueno@ibmcp.upv.es). All constructs were transformed into homozygous tfl1-1 plants using the floral dip method (S12). For each genomic construct, several independent transgenic lines were obtained and analyzed (7 for pASM4, 31 for pASM6 and 65 for pASM8). Gene aliases and corresponding gene identifiers are listed in expressed by either method, had been identified by ChIP-Seq peak(s) specific to the gene (i.e., a peak that was not within 3 kb upstream or 1 kb downstream of any other gene); the SMZ peak had another associated gene, AT3G55000, which was not detected as differentially expressed in the microarray experiments; and the AP1 peaks were also associated to AT1G69130, which codes for a pre-tRNA (not represented in the microarrays used). These observations suggest that the limited overlap between the ChIP-Seq and microarray-selected gene sets is not primarily a result of the intrinsic difficulties in assigning peaks to genes on the basis of distance. over the uninduced control ChIP sample and normalized using the two reference genomic regions (REF1 and REF2; see Table S12 ). Error bars indicate standard deviations. In most cases, the genomic regions that were amplified corresponded to the highest ChIP-Seq peaks within the 3 kb upstream to 1 kb downstream region of the respective genomic loci. In case of AP2 and TOE1, we selected peaks that were positioned approximately 4 kb (TOE1) or 3 kb (AP2) upstream of the transcriptional start of the respective genes. Gene aliases and corresponding gene identifiers are listed in Table S12 . from it follow a uniform distribution, and that distances coming from a true enriched signal are non-uniform. To separate these two sets of distances, the method of Storey (S9) Tables and legends   Table S1 : Genes identified as differentially expressed after AP1 activation. Genes for which the Benjamini & Hochberg-adjusted P-value was <0.05 in at least one of the timepoints and microarray platforms used (Agilent and/or Operon) were initially considered as differentially expressed in response to AP1 activation ("Agilent and_or Operon_BH-0h" worksheet). Genes that were differentially expressed at timepoint 0h were excluded from the analysis of the corresponding platform data. Results are summarized per time point (0h, 2h, 4h, 8h, 12h), platform (Agilent or Operon) and, in the case of the Operon oligo microarrays, per scanner used (GenePix 4200A or 4000B), and arranged accordingly in columns (0h Agilent, 0h Operon 4200 SCAN, 0h Operon 4000 SCAN, 2h Agilent, etc.) using values of "0" (no differential expression) and "1" (differential expression). Fold change, P-value, and
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Figures and legends
Benjamini & Hochberg-adjusted P-value (BH) are also shown. A gene may be listed more than once if probes assigned to different gene models or variants were present, either within or across platforms. A total of 6600 different genes (using probes for 6731 different gene/gene variants) were identified as differentially expressed. A further selection for robust differential expression was implemented by applying an absolute fold-change (FC) cutoff of 1.8 ("Agilent and_or Operon BH&FC-0h" worksheet), which led to the identification of 1366 different genes (using probes for 1392 gene/gene variants).
Supplementary file: Table S1 .xls Table S2 : Genomic regions identified as enriched in AP1 ChIP-Seq experiments. A total of 14,174 genomic regions were identified in the AP1 ChIP-Seq experiments ("ChIP-Seq peaks" worksheet), 1,942 of which were classified as statistically significant (FDR<0.001, which corresponded to a peak score >79.6). Of those 1,942 enriched regions, 1,678 were within 3 kb upstream from the start to 1 kb downstream from the end of TAIR8 annotated genes: a total of 2298 different genes were identified, which resulted in 2,653 different peakgene combination ("ChIP-Seq peak -Gene pairs" worksheet; one peak can be associated with more than one gene, and vice versa). These 2,298 genes are classified as "Putative direct targets". The position of the peak with a score higher than 79.6 (or peaks, if more than one peak above that threshold is associated with a gene) with respect to the corresponding gene is worksheet show: a unique identifier for each peak, which consists of the chromosome number and the coordinate position for the peak maximum (ChIP-Seq peak ID column); the start and end coordinates of the peak region (Start coordinates, End coordinates); the position, in chromosome coordinates, of the nucleotide within the peak with the highest score (ChIP-Seq peak score position); the peak score, which is the maximum score of any of the nucleotides encompassed by the peak (ChIP-Seq peak score); and the distance between the start and the end of the peak (Peak length). Additional columns in the ChIP-Seq peak -Gene pairs worksheet show: the position of the peak with respect to the gene (Relative position to the start of the gene, and Relative position to the end of the gene), a unique identifier for the gene associated with the peak (Gene ID (At#)), and the distance from the start to the end of the gene according to TAIR8 annotation (Gene length).
Supplementary file: Table S2 .xls Table S3 : High-confidence AP1 targets. High-confidence target genes were those identified as differentially expressed (BH< 0.05 and FC> 1.8) and for which a ChIP-Seq AP1
binding site was detected (FDR< 0.001, peak score> 79.6) within the region from 3 kb upstream from the start to 1 kb downstream from the end of the annotated gene (see Fig. 1D ).
For each gene, both the ChIP-Seq results and the microarray data are presented in the table.
The position of the peak with a score higher than 79.6 (or peaks, if more than one peak above that threshold is associated with a gene) with respect to the corresponding gene is indicated Supplementary file: Table S3 .xls proportions (with 1 degree of freedom, P-value < 0.001) (worksheet "chi-square").
Supplementary file: Table S5 .xls Table S6 : Necessity and sufficiency of AP1 for affecting the expression of highconfidence target genes. To obtain evidence for the necessity of AP1 as an inductive (or repressing) factor of the high-confidence target genes, we performed a gene expression profiling experiment comparing ap1-1 mutant and wild-type inflorescences using Agilent version 1 microarrays (worksheet "AP1 necessity (ap1 vs wt)"). If AP1 activity were necessary, AP1 target genes that were found to be induced upon AP1-GR activation would be expected to be down-regulated when comparing gene expression in ap1 versus wild-type inflorescences and, conversely, AP1 target genes that were repressed after AP1-GR activation would be expected to be up-regulated in the ap1 versus wild type comparison, as ap1-1 is a loss-of-function mutant. Sixteen genes (out of the 197 high-confidence targets that were identified through the Agilent microarrays; Table S3 ) showed expression changes in the ap1 vs wild type comparison that followed the above logic. That this percentage is low (8.1%) is expected, given that the plant materials and the developmental stages that were assayed in the AP1-GR ap1 cal time course and in the ap1 versus wild type comparison were necessarily different, and because in ap1 mutant plants the (partially) functionally redundant homolog CAL is present (and therefore masks part of the effects of the loss of AP1 function).
For the sixteen genes, the Fig. 1B ) is indicated.
Supplementary file: Table S9 .xls Table S10 : Mapping results for the Illumina sequencing runs. Results are shown per flow cell lane. The number of reads (sequences) that were mapped in the Arabidopsis chromosomes (chr1-5), and in the chloroplast and mitochondrial genomes, is indicated, as well as the total number of mapped reads. Column "% chr1-5" shows the percent of the total number of reads that was mapped to chromosomes 1 through 5 (i.e., excluding chloroplastand mitochondria-mapped reads). 
Mapping results
